Los Angeles, USA and Copenhagen, Denmark – Sept. 17, 2025 – Eyenuk, a global leader in AI-powered eye screening, today announced that its EyeArt® AI Eye Screening System has been …
Los Angeles, Jan. 06, 2025 — Eyenuk, a global artificial intelligence (AI) digital health company and leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced …
LOS ANGELES, November 28th, 2023 – Eyenuk, Inc., a leading global digital health company specializing in artificial intelligence (AI), today stands shoulder to shoulder with the National Eye Institute (NEI), …
This clearance expands the label of its flagship product, the EyeArt® AI system, broadening the choice for primary care clinics to screen people with diabetes Company’s FDA clearance also includes …
Leads Expansion of Commercial Team Toward Next Stage of Growth LOS ANGELES – February 16, 2023 – Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in …
Eyenuk Welcomes Paul Praino as Chief Commercial Officer Read More »
The approval allows Eyenuk’s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31, …
Brings Eyenuk’s total funding to over $43 million Funding round led by AXA IM Alts; joined by T&W Medica A/S, Kendall Capital Partners, and others Eyenuk adds three new board …
Academic leaders will review their experience with the technology during a symposium at AAO 2022, the American Academy of Ophthalmology annual meeting CHICAGO, September 30, 2022 — From the American …
Program selects Eyenuk’s EyeArt AI system to make vision-saving screening more accessible in remote Ontario communities LOS ANGELES and TORONTO, August 16, 2022 – Vision Loss Rehabilitation Canada (VLRC), Canada’s …
LOS ANGELES, June 8, 2022 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI …
LOS ANGELES, June 1, 2022 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI …
Harnessing Artificial Intelligence, Eyenuk is Focused on Improving Population Health Outcomes by Bringing Diabetes Complication Management to Point-of-Care and Community Settings WASHINGTON, March 10, 2022 – Population Health Alliance …
A new diabetic retinopathy screening benefit enabled by the EyeArt® AI system is made available by Discovery Health, a global leader in Healthcare and Financial Services LOS ANGELES, December 7, …
Eyenuk Launches EyeArt AI System in South Africa in Collaboration with Discovery Health Read More »
The published results demonstrate exceptional EyeArt accuracy in a pre-registered, prospective, multicenter clinical trial Los Angeles, November 15, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and …
The CMS Final Rule establishes a national payment for CPT code 92229 that describes Eyenuk’s FDA-cleared EyeArt® AI system and confirms that AI can be used to close care gaps …
LOS ANGELES, July 26, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that …
Financing led by AXA IM’s Impact Investing strategy Los Angeles, CA, July 20, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader …
Upcoming Webinar Series to Feature Customer Clinical Successes Los Angeles, CA, May 12, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader …
EyeArt is the First FDA Cleared AI Technology for Autonomous Detection of Both More than mild and Vision-Threatening Diabetic Retinopathy Los Angeles, CA, August 5, 2020 — Eyenuk, Inc., a …
Artificial intelligence could help prevent eye damage and sight loss in people with diabetes and save NHS millions of pounds annually MONDAY 6THJULY 2020 Results from the largest study of …
